Table 1.
Experimental design of five reduction in liver infection experiments showing group sizes
| Experiment ID | Administrations (in vaccine groups) | Control groups (# mice/group) | Vaccine groups (# mice/group) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AB317 | Naïve (No vaccine) | Background (d-luciferin) | RTS,S dose levels | ||||||
| 0.05 μg | 0.2 μg | 1 μg | 5 μg | 10 μg | |||||
| 2x Trial 1 | 2 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
| 2x Trial 2 | 2 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
| 2x Trial 3 | 2 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
| 3x Trial 1 | 3 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
| 3x Trial 2 | 3 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
Different doses of RTS,S in a constant amount of AS01 adjuvant were administered intramuscularly at 3-week intervals, with IV challenge from 2000 tgPb-PfCSP sporozoites 2-weeks after the last vaccination. For the AB317 groups, only one administration was given 16 h prior to challenge.